The Accelerating Medicines Partnership Alzheimer's Disease (AMP-AD) is a precompetitive consortium that brings together academic researchers, pharmaceutical companies, and patient advocacy organizations to identify and validate novel therapeutic targets for Alzheimer's Disease. The partnership generates and shares large-scale multi-omics data to accelerate drug discovery.
AMP-AD was launched by the NIH in 2014 as part of the Accelerating Medicines Partnership (AMP) initiative:[1]
The consortium aims to:[2]
RNA-seq from multiple brain regions:[3]
Mass spectrometry-based proteomics:
Metabolite profiling:
Integration with:
AMP-AD has identified numerous novel targets:[4]
Network analysis reveals:[5]
Integrated analysis identifies:[6]
Computational approaches have identified:[7]
Studies show:[8]
AMP-AD data support:
The consortium helps reduce failure risk by:
Open data access accelerates:
All data are publicly available:[1:1]
AMP-AD Official Website. 2024. ↩︎ ↩︎
Gauther L, et al. Integrative network analysis identifies novel AD targets. Nature Reviews Drug Discovery. 2018. ↩︎
Swarup V, et al. Identification of novel transcriptional networks in AD. Nature Neuroscience. 2017. ↩︎
Chen JA, et al. Novel tau targets from AMP-AD consortium. Acta Neuropathologica Communications. 2020. ↩︎
Wang M, et al. Genome-wide profiling in AMP-AD identifies gene networks. Nature Neuroscience. 2018. ↩︎
Brase L, et al. Integrative analysis of multi-omics data in AD. Systems Biology. 2016. ↩︎
Tian C, et al. Network-based drug repositioning for AD. Nature Communications. 2021. ↩︎
Barnes LL, et al. APOE4 and sex interact to influence AD biomarkers. Neurology. 2022. ↩︎